SARC046 Opens to Enrollment

SARC is pleased to announce that SARC046 is now open and actively recruiting patients at Dana-Farber Cancer Institute. This Phase II trial is evaluating nab-sirolimus in adults with progressing or symptomatic epithelioid hemangioendothelioma (EHE).

Led by Dr. Michael Wagner of Dana-Farber Cancer Institute, the overall principal investigator of SARC046. In addition to Dana-Farber Cancer Institute, four additional U.S. sites are expected to open enrollment in the coming months.

A hallmark of SARC’s research model is the integration of patient advocacy directly into our clinical trials. By embedding patient advocates within study teams, we ensure that trial design and execution reflect the lived experiences, priorities, and needs of those facing sarcoma. For SARC046, SARC extends its gratitude to the EHE Foundation for its partnership and support in identifying the EHE patient advocate who has helped to guide this effort.